002044 · SZSE · China
health-100.cnFinancials as of FY2025
Runs licensed health screening centers across Chinese cities so employers can meet government documentation requirements through a single contract.
What this company is and how it runs — written from structure, not news.
Meinian Onehealth signs single contracts with Chinese employers to run the annual health screenings that occupational regulations require, operating licensed medical facilities across multiple tier-1 and tier-2 cities so that one contract can cover employees wherever they are based. Because Chinese law requires a licensed facility in the same municipal jurisdiction as each employee, a competitor holding licences in only some of those cities cannot bid on the full contract without leaving the employer out of compliance in the uncovered cities — which is what keeps each contract in place once signed. Years of employee health records then flow into the corporate HR system through a standardized reporting interface, and switching providers would mean untangling that integration and losing the longitudinal data that employers use for insurance risk submissions. The whole structure rests on the government continuing to allow private licensed facilities to issue occupationally required health reports; if that function were shifted to public hospitals, the municipal licence stack that makes Meinian's contracts possible would stop conferring the right to issue them.
How does this company make money?
The company charges individual patients a fee for each examination they receive. It also signs annual contracts with corporations that cover a set number of employee screenings per year. On top of those two income streams, it earns additional money when patients or employers add specialized tests or supplemental screening services beyond the standard package.
What makes this company hard to replace?
Corporate clients have employee health records and annual screening schedules built into their existing HR systems, so switching providers means untangling that integration and rebuilding it with someone else. Individual patients lose years of accumulated health trend data if they move to a different provider — that historical record is what makes each new annual screening meaningful for tracking changes over time.
What limits this company?
Every completed health report requires a certified radiologist to personally review the imaging scans and a licensed laboratory technician to sign off on the blood work before the report can be issued. Chinese regulations do not allow software or equipment to substitute for those sign-offs. So even if a facility adds more CT scanners or opens more appointment slots, output cannot increase once the credentialed staff are already working at full capacity.
What does this company depend on?
The company cannot operate without municipal healthcare facility licenses in each city it serves. It also depends on certified radiologists and laboratory technicians holding Chinese medical credentials, since regulations require their personal sign-off on every report. CT scanners, ultrasound machines, clinical laboratory consumables, and diagnostic reagents are needed to run the screenings themselves. Appointment scheduling and patient management software keeps the facilities running day to day.
Who depends on this company?
Chinese corporations that rely on it to document annual employee screenings would face compliance gaps with occupational health regulations if it stopped operating. Individual patients in tier-1 cities who use it for consolidated preventive screening — the kind that requires multiple specialist appointments in one visit — would lose access to that convenience. Chinese health insurance providers would lose the standardized screening data they use to assess risk and calculate premiums.
How does this company scale?
Scheduling software and standardized screening protocols can be rolled out to new locations at low additional cost — those parts replicate easily. What does not scale through automation is the credentialed medical staff: Chinese regulations require licensed physicians to validate results and radiologists to interpret imaging at every facility, so each new city requires recruiting and retaining qualified people before that location can issue a single completed report.
What external forces can significantly affect this company?
Changes to Chinese government healthcare policy — particularly anything affecting reimbursement for preventive care or the rules about which facility types can issue occupational health reports — could reshape the entire business overnight. Municipal licensing rules already restrict where and how fast the company can expand into new cities. On the demand side, China's aging population is pushing more people toward early detection screenings, which increases the volume of work flowing through these facilities.
Where is this company structurally vulnerable?
If Chinese regulators decided that occupationally required health screenings must be performed at designated public hospitals rather than private licensed facilities, the municipal license stack this company has built would no longer carry the legal authority to issue the reports that make corporate contracts valid. The licenses and the reporting integration only have commercial value because regulations currently allow private licensed facilities to fulfill that function — remove that, and the entire structure loses its foundation.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped declining and bounced upward, and (2) current price is back inside or just above that zone after a meaningful drawdown from peak. The retest is a real one — the stock is not at a new all-time high being measured as a low.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Three observations describe the present configuration: the current close sits below the 40-week SMA (the conventional 'below 200-day SMA'), the company has reported positive net income in each of the last three annual periods, and operating cash flow exceeded net income in the most recent annual period.
Three observations describe the present configuration: the most recent run of consecutive down-close weeks is at or near the configured ceiling, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked equity ratio is in the upper range against peers.
Three observations describe the present configuration: drawdown from the trailing peak is significant, free cash flow has been positive in each of the last three annual periods, and operating cash flow exceeded net income in the most recent annual period.
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and the equity ratio is in the elevated industry-benchmarked range. The configuration describes a depressed-price, profitable, equity-funded profile.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph